CCR2-64I polymorphism is associated with Non-Small Cell Lung Cancer in Tunisian patients

Human Immunology

Volumn 76, Issue 5, 2015, Pages 348-354

  Rafrafi, Ahlem ^a   Kaabachi, Safa ^a   Kaabachi, Wajih ^a   Chahed, Besma ^a   Amor, Amira Ben ^a   Mbarik, Marwa ^a   Charrad, Rihab ^a   Salah, Marwa Ouled ^a   Hamzaoui, Kamel ^a   Sassi, Fayçal Haj ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

CCR2 64I; CXCL12 3'A; Lung cancer; PCR; RFLP; Single nucleotide polymorphism

Indexed keywords

CHEMOKINE RECEPTOR CCR2; MESSENGER RNA; CCR2 PROTEIN, HUMAN; STROMAL CELL DERIVED FACTOR 1;

ADULT; ALLELE; ARTICLE; CANCER RISK; CCR2 64I GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HOMOZYGOTE; HUMAN; HUMAN CELL; LARGE CELL LUNG CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL LUNG CARCINOMA; TUNISIAN; AGED; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LUNG TUMOR; NUCLEOTIDE SEQUENCE; RISK; TUNISIA;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOKINE CXCL12; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, CCR2; RISK; TUNISIA;

EID: 84928584677     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2015.03.003     Document Type: Article

References (56)

1. Blot W.J., Mc Laughlin J.K. Are women more susceptible to lung cancer?. J. Natl. Cancer Inst. 2004, 96:826-834.
2. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics. Cancer. J. Clin. 2005, 55:30.
3. Hoffman P.C., Mauer A.M., Vokes E.E. Lung cancer. Lancet 2000, 355:479-485.
4. U.S. Department of Health and Human Services. 2010. How Tobacco Smoke Causes Disease: The Biology and Behavioral Basis for Smoking-Attributable Disease: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health.
5. J.A. Burger, J.K. Thomas, CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107, 1761-1767.
6. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008, 267:226-244.
7. Darash-Yahana M., Pikarsky E., Abramovitch R., Zeira E., Pal B., Karplus R., et al. Role of high expression levels of CXCR4 in tumor growth, vascularization, and metastasis. FASEB J. 2004, 18:1240-1242.
8. Strieter R.M., Belperio J.A., Phillis R.J., Keane M.P. CXC chemokines in angiogenesis of cancer. Semin. Cancer Biol. 2004, 14:195-200.
9. Phillips R.J., Burdick M.D., Lutz M., Belperio J.A., Keane M.P., Strieter R.M. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 2003, 167:1676-1686.
10. Song N., Huang Y., Shi H., Yuan S., Ding Y., Song X., et al. Overexpression of platelet derived growth factor-BB increases tumor pericyte content via stromal-derived factor-1alpha/CXCR4 axis. Cancer Res. 2009, 69:6057-6064.
11. Petty J.M., Sueblinvong V., Lenox C.C., Jones C.C., Cosgrove G.P., Cool C.D., et al. Pulmonary stromal-derived factor-1 expression and effect on neutrophil recruitment during acute lung injury. J. Immunol. 2007, 178:8148-8157.
12. Watanabe M.A., de Oliveia Cavassin G.G., Orellana M.D., et al. SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1 infected individuals. Microb. Pathog. 2003, 35:31-34.
13. De Oliveira C.E., Cavassin G.G., Perim Ade L., Nasser T.F., de Oliveira K.B., Fungaro M.H., et al. Stromal cell-derived factor-1 chemokine gene variant in blood donors and chronic myelogenous leukemia patients. J. Clin. Lab. Anal. 2007, 21:49-54.
14. Razmkhah M., Doroudchi M., Ghayumi S.M., Erfani N., Ghaderi A. Stromal cell BX5 derived factor-1 (SDF-1) gene and susceptibility of Iranian patients with lung cancer. Lung Cancer 2005, 49:311-315.
15. Nakashima E., Mukaida N., Kubota Y., Kuno K., Yasumoto K., Ichimura F., et al. Human MCAF gene transfer enhances the metastatic capacity of a mouse cachectic adenocarcinoma cell line in vivo. Pharm. Res. 1995, 12:1598-1604.
16. Zachariae C.O., Anderson A.O., Thompson H.L., Appella E., Mantovani A., Oppenheim J.J., et al. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line. J. Exp. Med. 1990, 171:2177-2182.
17. Becker S., Quay J., Koren H.S., Haskill J.S. Constitutive and stimulated MCP-1, GRO alpha, beta, and gamma expression in human airway epithelium and bronchoalveolar macrophages. Am. J. Physiol. 1994, 266:L278-L286.
18. Antoniades H.N., Neville-Golden J., Galanopoulos T., Kradin R.L., Valente A.J., Graves D.T. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. U.S.A. 1992, 89:5371-5375.
19. Car B.D., Meloni F., Luisetti M., Semenzato G., Gialdroni-Grassi G., Walz A. Elevated IL-8 and MCP-1 in the bronchoalveolar lavage fluid of patients with idiopathic pulmonary fibrosis and pulmonary sarcoidosis. Am. J. Respir. Crit. Care Med. 1994, 149:655-659.
20. Watanabe H., Miki C., Okugawa Y., Toiyama Y., Inoue Y., Kusunoki M. Decreased expression of monocyte chemoattractant protein-1 predicts poor prognosis following curative resection of colorectal cancer. Dis. Colon Rectum. 2008, 51:1800-1805.
21. Salcedo R., Ponce M.L., Young H.A., Wasserman K., Ward J.M., Kleinman H.K., et al. Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood 2000, 96:34-40.
22. Lu Y., Cai Z., Galson D.L., Xiao G., Liu Y., George D.E., et al. Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 2006, 66:1311-1318.
23. Youngs S.J., Ali S.A., Taub D.D., Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. Int. J. Cancer 1997, 71:257-266.
24. Coelho A., Matos A., Catarino R., Pinto D., Pereira D., Lopes C., et al. Protective role of the polymorphism CCR2-64I in the progression from squamous intraepithelial lesions to invasive cervical carcinoma. Gynecol. Oncol. 2005, 96:760-764.
25. Zafiropoulos A., Crikas N., Passam A.M., Spandidos D.A. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J. Med. Genet. 2004, 41:e59.
26. Zambra F.M.B., Biolchi V., Brum I.S., Bogo Chies J.A. CCR2 and CCR5 genes polymorphisms in benign prostatic hyperplasia and prostate cancer. Hum. Immunol. 2013, 74:1003-1008.
27. Pechkovsky D.V., Goldmann T., Ludwig C., Prasse A., Vollmer E., Müller-Quernheim J., et al. CCR2 and CXCR3 agonistic chemokines are differently expressed and regulated in human alveolar epithelial cells type II. Respir. Res. 2005, 6:75.
28. Kijima T., Maulik G., Ma P.C., Tibaldi E.V., Turner R.E., Rollins B., et al. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. Cancer Res. 2002, 62:6304-6311.
29. Shalekoff S., Schramm D.B., Lassaunière R., Picton A.C.P., Tiemessen C.T. Differences are evident within the CXCR4-CXCL12 axis between ethnically divergent South African populations. Cytokine 2013, 61:792-800.
30. Asai H., Fujiwara H., An J., Ochi T., Miyazaki Y., Nagai K., et al. Co-introduced functional CCR2 potentiates in vivo anti-lung cancer functionality mediated by T cells double gene-modified to express WT1-specific T-cell receptor. PLoS One 2013, 8(2):e56820.
31. Rafrafi A., Chahed B., Kaabachi S., Kaabachi W., Maalmi H., Hamzaoui K., Haj Sassi F. Association of IL-8 gene polymorphisms with non small cell lung cancer in Tunisia: a case control study. Hum. Immunol. 2013, 74:1368-1374.
32. I. Vande Broek, X. Leleu, R. Schots, T. Facon, K. Vanderkerken, B. Van Camp, I. Van Riet. Clinical significance of chemokine receptor (CCR1, CCR2 and CXCR4) expression in human myeloma cells: the association with disease activity and survival. Haematological (2006) 91 200-206.
33. Lu Y., Cai Z., Xiao G., Liu Y., Keller E.T., Yao Z., et al. CCR2 expression correlates with prostate cancer progression. J. Cell Biochem. 2007, 101:676-685.
34. Zhang X., Qin X., Qin C.Y., Yin Y., Chen Y., Zhu H. Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol. Immunother. 2013, 62(3):563-570.
35. L. Yang, G.L. Shi, C.X. Song, S.F. Xu. Relationship between genetic polymorphism of MCP-1 and non-small-cell lung cancer in the Han nationality of North China. Genet. Mol. (2010) 9 (2) 765-771.
36. Attar R., Agachan B., Kuran S.B., Cacina C., Sozen S., Yurdum L.M., et al. Association of CCL2 and CCR2 gene variants with endometrial cancer in Turkish women. In Vivo 2010, 24:243-248.
37. Narter K.F., Agachan B., Sozen S., Cincin Z.B., Isbir T. CCR2-64I is a risk factor for development of bladder cancer. Genet. Mol. 2010, 9(2):685-692.
38. Yeh C.B., Tsai H.T., Chen Y.C., Kuo W.H., Chen T.Y., Hsieh Y.H., et al. Genetic polymorphism of CCR2-64I increased the susceptibility of hepatocellular carcinoma. J. Surg. Oncol. 2010, 102:264-270.
39. Bektas-Kayhan K., Unur M., Boy-Metin Z., Cakmakoglu B. MCP-1 and CCR2 gene variants in oral squamous cell carcinoma. Oral Dis. 2012, 18:55-59.
40. Ch Young A., Jeongseon K. Association of polymorphisms in the MCP-1 and CCR2 genes with the risk of cancer: a meta-analysis. Cytokine 2013, 64(1):213-220.
41. Chatterjee K., Dandara C., Hoffman M., Williamson A.L. CCR2-V64I polymorphism is associated with increased risk of cervical cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer 2010, 10:278.
42. Chen M.K., Yeh K.T., Chiou H.L., Lin C.W., Chung T.T., Yang S.F. CCR2-64I gene polymorphism increase susceptibility to oral cancer. Oral Oncol. 2011, 47:577-582.
43. Pandith A.A., Khan N.P., Azad N.A., Khan M.S., Wani M.S. Association of chemokine and chemokine receptor gene polymorphis (MCP1 A-2518G and CCR2-64I) urinary bladder cancer: a study in Kachmiri Population. Am. J. Mol. Cell. Biol. 2013, 2(1):1-13.
44. Salem A.H., Farid E., Fadel R., Abu-Hijleh M., Almawi W., Han K.A., Batzer M. Distribution of four HIV type 1-resistance polymorphisms (CCR5-δ 32, CCR5-m303, CCR2-64I, and SDF1-3'A) in the Bahraini population. AIDS Res. Hum. Retroviruses 2009, 25(10):973-977.
45. Smith M.W., Dean M., Carrington M., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Science 1997, 277:959-965.
46. Su B., Jin L., Hu F., et al. Distribution of two HIV-1-resistant polymorphisms (SDF1-3'A and CCR2-64I) in East Asian and world populations and its implication in AIDS epidemiology. Am. J. Hum. Genet. 1999, 65:1047-1053.
47. Singh V., Srivastava P., Srivastava N., Rakesh Kapoor R., Mittal R.M. Association of inflammatory chemokine gene CCL2I/D with bladder cancer risk in North Indian population. Mol. Biol. Rep. 2012, 39:9827-9834.
48. Hsin-Hung W., Tsung-Hsien L., Yi-Torng T., Shiuan-Chih Ch., Shun-Fa Y., Shu-Kuei L., et al. Relationships of single nucleotide polymorphisms of monocyte chemoattractant protein 1 and chemokine receptor 2 with susceptibility and clinicopathologic characteristics of neoplasia of uterine cervix in Taiwan women. Reprod. Sci. 2013, 20(10):1175-1183.
49. Coelho A., Calcada C., Catarino R., Pinto D., Fonseca G., Medeiros R. CXCL12-3'A polymorphism and lung cancer metastases protection: new perspectives in immunotherapy?. Cancer Immunol. Immunother. 2006, 55:639-643.
50. Coelho A., Pereira D., Nogal A., Pinto D., Catarino R., Araujo A., et al. CXCL12 chemokine genotypes as predictive biomarkers of ovarian cancer outcome. Mol. Med. Rep. 2009, 2:103-106.
51. Kruszyna Ł., Lianeri M., Rubis B., Knuła H., Rybczyńska M., Grodecka-Gazdecka S., Jagodziński P.P. CXCL12-3' G801A polymorphism is not a risk factor for breast cancer. DNA Cell Biol. 2010, 29(8):423-427.
52. De Oliveira K.B., Maeda Oda J.M., Voltarelli J.C., Nasser T.F., Ono M.A., Fujita T.C., Matsuo T., Ehara Watanabe M.A. CXCL12 rs1801157 polymorphism in patients with breast cancer, hodgkin's lymphoma, and non-hodgkin's lymphoma. J. Clin. Lab. Anal. 2009, 23:387-393.
53. De Oliveira K.B., Guembarovski R.L., Maeda Oda J.M., Mantovani M.S., Carrera C.M., Vissoci Reiche E.M., Voltarelli J.C., Amaral Herrera A.C., Watanabe M.A.E. CXCL12 rs1801157 polymorphism and expression in peripheral blood from breast cancer patients. Cytokine 2011, 55:260-265.
54. Dimberg J., Hugander A., Lofgren S., Wagsater D. Polymorphism and circulating levels of the chemokine CXCL12 in colorectal cancer patients. Int. J. Mol. Med. 2007, 19:11-15.
55. Gong H., Tan M., Wang Y., Shen B., Liu Z., Zhang F., et al. The CXCL12 G801A polymorphism and cancer risk: evidence from 17 case-control studies. Gene 2012, 509:228-231.
56. Shen W., Cao X., Xi L., Deng L. CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis. Mol. Biol. Rep. 2012, 39:2039-2044.